Therefore, the use of Dicumarol among stroke patients with atrial fibrillation, who often have more severe strokes and poorer neurological outcomes, may provide additive benefits from both its anticoagulant effects and SWELL1 channel blockade. This evidence concerns the gene LRRC8A and atrial fibrillation.